Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, January 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 14,197 followers.

ベキサロテンのPhase2試験（BEAT-AD）結果の報告によると、ApoE4ノンキャリアーの患者さんにおいて、脳内アミロイドβ量が減少したことを確認した。ApoE4キャリアーの患者さんでは変化なし。https://t.co/sh3l9KZS0K https://t.co/y5grOghMMO

RT @AlzheimersRes: New research from Dr Jeffrey Cummings et al: proof-of-concept trial of bexarotene in moderate Alzheimer’s disease https:…

Two new reports on the RXR agonist #Bexarotene as treatment for Alzheimer's #OpenAccess https://t.co/9Po4dSpRcw and https://t.co/kzHjwWVhhi

New research from Dr Jeffrey Cummings et al: proof-of-concept trial of bexarotene in moderate Alzheimer’s disease https://t.co/e8404FFnYF

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.